Functional impairment of common gynecologic diseases in the “Me Too” era

Elizabeth A. Stewart; Stewart EA

doi:10.1016/j.fertnstert.2019.05.036

Functional impairment of common gynecologic diseases in the “Me Too” era

Elizabeth A. Stewart, Stewart EA

Fertility and sterility · 2019 · vol. 112(3) , pp. 477 · doi:10.1016/j.fertnstert.2019.05.036 · PMID:31327471 · W2961277476

letter OA: bronze CC0

🔓 Open OA copy View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This paper examines how common gynecologic diseases and their associated functional impairments are perceived and addressed within the context of the "Me Too" movement.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Female Humans Hydrocarbons, Fluorinated Pain Pyrimidines

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials 2019

References (5)

Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials via openalex
W2408558883 via openalex
W2512047488 via openalex
W2798414871 via openalex
W2896492055 via openalex

Source provenance

europepmc: last seen: 2026-09-20T09:27:46.357103+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-05-13T22:22:41.077124+00:00

License: CC0 · commercial use OK

[1] Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials 2019